RemeGen Co., Ltd.
Research RemeGen Co., Ltd. (688331.SS) on Bullrun: market cap CNY 56.42B, P/E 9.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker688331.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCNY
- Market capCNY 56.42B
- P/E9.6
- Financial periodFY2025
- RevenueCNY 3.24B
- Revenue growth89.5%
- Net incomeCNY 709.65M
- Free cash flow-CNY 147.66M
- Gross margin86.9%
Valuation Snapshot
latest market cap is CNY 56.42B; P/E is 9.6.
Peer valuation comparison
Latest P/E is 9.61x versus a Healthcare sector median of 21.69x (55.7% below).
Latest P/E is 9.61x versus a China median of 16.26x (40.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 3.24B | CNY 709.65M | -CNY 147.66M | 86.9% | 1.29 | CNY 1.15B | CNY 2.20B | CNY 3.61B |
| FY2024 | CNY 1.71B | -CNY 1.47B | -CNY 1.44B | 80.0% | -2.73 | CNY 759.53M | CNY 2.67B | CNY 1.99B |
| FY2023 | CNY 1.08B | -CNY 1.51B | -CNY 2.35B | 76.5% | -2.8 | CNY 726.55M | CNY 1.26B | CNY 3.44B |
| FY2022 | CNY 767.78M | -CNY 998.83M | -CNY 2.02B | 64.8% | -1.88 | CNY 2.07B | CNY 165.04M | CNY 4.98B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | CNY 56.42B | 9.6 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CNY.
About RemeGen Co., Ltd.
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is RemeGen Co., Ltd.'s market cap?
RemeGen Co., Ltd.'s market capitalization is CNY 56.42B.
What is RemeGen Co., Ltd.'s P/E ratio?
RemeGen Co., Ltd.'s price-to-earnings (P/E) ratio is 9.6.
What does RemeGen Co., Ltd. do?
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors.